These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. An anti-MUC1 antibody-calicheamicin conjugate for treatment of solid tumors. Choice of linker and overcoming drug resistance. Hamann PR; Hinman LM; Beyer CF; Greenberger LM; Lin C; Lindh D; Menendez AT; Wallace R; Durr FE; Upeslacis J Bioconjug Chem; 2005; 16(2):346-53. PubMed ID: 15769088 [TBL] [Abstract][Full Text] [Related]
8. Linker technologies for antibody-drug conjugates. Nolting B Methods Mol Biol; 2013; 1045():71-100. PubMed ID: 23913142 [TBL] [Abstract][Full Text] [Related]
9. Tumor delivery and in vivo processing of disulfide-linked and thioether-linked antibody-maytansinoid conjugates. Erickson HK; Widdison WC; Mayo MF; Whiteman K; Audette C; Wilhelm SD; Singh R Bioconjug Chem; 2010 Jan; 21(1):84-92. PubMed ID: 19891424 [TBL] [Abstract][Full Text] [Related]
10. In vivo drug-linker stability of an anti-CD30 dipeptide-linked auristatin immunoconjugate. Sanderson RJ; Hering MA; James SF; Sun MM; Doronina SO; Siadak AW; Senter PD; Wahl AF Clin Cancer Res; 2005 Jan; 11(2 Pt 1):843-52. PubMed ID: 15701875 [TBL] [Abstract][Full Text] [Related]
11. Novel immunoconjugates comprised of streptonigrin and 17-amino-geldanamycin attached via a dipeptide-p-aminobenzyl-amine linker system. Burke PJ; Toki BE; Meyer DW; Miyamoto JB; Kissler KM; Anderson M; Senter PD; Jeffrey SC Bioorg Med Chem Lett; 2009 May; 19(10):2650-3. PubMed ID: 19386499 [TBL] [Abstract][Full Text] [Related]
12. The Chemical Design and Synthesis of Linkers Used in Antibody Drug Conjugates. Frigerio M; Kyle AF Curr Top Med Chem; 2017; 17(32):3393-3424. PubMed ID: 29357801 [TBL] [Abstract][Full Text] [Related]
13. Natural products as exquisitely potent cytotoxic payloads for antibody- drug conjugates. Gromek SM; Balunas MJ Curr Top Med Chem; 2015; 14(24):2822-34. PubMed ID: 25487009 [TBL] [Abstract][Full Text] [Related]
14. Antibody-drug conjugates: an emerging modality for the treatment of cancer. Leal M; Sapra P; Hurvitz SA; Senter P; Wahl A; Schutten M; Shah DK; Haddish-Berhane N; Kabbarah O Ann N Y Acad Sci; 2014 Aug; 1321():41-54. PubMed ID: 25123209 [TBL] [Abstract][Full Text] [Related]
15. Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity. Doronina SO; Mendelsohn BA; Bovee TD; Cerveny CG; Alley SC; Meyer DL; Oflazoglu E; Toki BE; Sanderson RJ; Zabinski RF; Wahl AF; Senter PD Bioconjug Chem; 2006; 17(1):114-24. PubMed ID: 16417259 [TBL] [Abstract][Full Text] [Related]
16. Comprehensive review on the elaboration of payloads derived from natural products for antibody-drug conjugates. Lu N; Wu J; Tian M; Zhang S; Li Z; Shi L Eur J Med Chem; 2024 Mar; 268():116233. PubMed ID: 38408390 [TBL] [Abstract][Full Text] [Related]
17. Recent Chemical Approaches for Site-Specific Conjugation of Native Antibodies: Technologies toward Next-Generation Antibody-Drug Conjugates. Yamada K; Ito Y Chembiochem; 2019 Nov; 20(21):2729-2737. PubMed ID: 30973187 [TBL] [Abstract][Full Text] [Related]
18. The next generation of antibody-drug conjugates comes of age. Beck A; Haeuw JF; Wurch T; Goetsch L; Bailly C; Corvaïa N Discov Med; 2010 Oct; 10(53):329-39. PubMed ID: 21034674 [TBL] [Abstract][Full Text] [Related]
19. Antibody-drug conjugates for the treatment of cancer. Flygare JA; Pillow TH; Aristoff P Chem Biol Drug Des; 2013 Jan; 81(1):113-21. PubMed ID: 23253133 [TBL] [Abstract][Full Text] [Related]
20. Selecting an optimal antibody for antibody-drug conjugate therapy: internalization and intracellular localization. Harper J; Mao S; Strout P; Kamal A Methods Mol Biol; 2013; 1045():41-9. PubMed ID: 23913140 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]